Abstract
The complete response (CR) rates in patients with multiple myeloma (MM) have been rapidly increasing after the approval of novel agents such as proteasome inhibitors, immunomodulatory drugs, histone deacetylase inhibitors, and monoclonal antibodies. Recently, patients administered with a combination of novel agents with autologous stem-cell transplantation achieved a 70% CR rate. The assessment of minimal residual disease (MRD) is necessary for effective stratification of the CR cases and the generation of accurate prognoses. This review summarizes recent topics pertaining to MRD detection methods (multiparameter flow cytometry, allele-specific oligonucleotide real-time quantitative polymerase chain reaction, droplet digital PCR, and next-generation sequencing) and the prognostic value of MRD assessment in patients with MM.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
